Federal Register / Vol. 83, No. 157 / Tuesday, August 14, 2018 / Notices 40303 

Print Format in Direct-to-Consumer 

Prescription Drug Advertisements on 

Risk Knowledge and Preference.’’ Drug 

Information Journal, vol. 36(3), pp. 693– 

705, 2002. 

7. Brief Summary and Adequate Directions 

for Use: Disclosing Risk Information in 

Consumer-Directed Print Advertisements 

and Promotional Labeling for 

Prescription Drugs. Revised Draft 

Guidance. Available at https://

www.fda.gov/downloads/Drugs/ 

GuidanceComplianceRegulatory

Information/Guidances/UCM069984.pdf. 

8. ‘‘Content of Risk Information in the Major 

Statement in Prescription Drug Direct-toConsumer Broadcast Advertisements; 

Establishment of a Public Docket; 

Request for Information and Comments.’’ 

August 21, 2017, 82 FR 39598. 

9. Betts, Kevin R., et al., ‘‘Serious and 

Actionable Risks, Plus Disclosure: 

Investigating an Alternative Approach 

for Presenting Risk Information in 

Prescription Drug Television 

Advertisements.’’ Research in Social and 

Administrative Pharmacy, 2017. 

10. Bhutada, N.S., B.L. Rollins, and M. Perri 

III, ‘‘Impact of Animated SpokesCharacters in Print Direct-to-Consumer 

Prescription Drug Advertising: An 

Elaboration Likelihood Model 

Approach.’’ Health Communication, vol. 

32, pp. 391–400, 2017. 

11. Zaichkowsky, J.L., ‘‘The Personal 

Involvement inventory: Reduction, 

Revision, and Application to 

Advertising.’’ Journal of Advertising, vol. 

23, pp. 59–70, 1994. 

12. Mackert, M., S.E. Champlin, K.E. Pasch, 

and B.D. Weiss, ‘‘Understanding Health 

Literacy Measurement Through Eye 

Tracking.’’ Journal of Health 

Communication, vol. 18, pp. 185–196, 

2013. 

13. Chiang, K.P. and A. Jackson, ‘‘The Impact 

of Health Literacy on Involvement and 

Attitude Toward Pharmaceutical Print 

Ads.’’ International Journal of 

Healthcare Management, vol. 9(1), pp. 

47–57, 2016. 

14. An, S. and N. Muturi, ‘‘Subjective Health 

Literacy and Older Adults’ Assessment 

of Direct-to Consumer Prescription Drug 

Ads.’’ Journal of Health Communication, 

vol. 16(3), pp. 242–255, 2011. 

15. Ball, J.G., D. Manika, and P. Stout, 

‘‘Consumers Young and Old: Segmenting 

the Target Markets for Direct-toConsumer Prescription Drug 

Advertising.’’ Health Marketing 

Quarterly, vol. 28(4), pp. 337–353, 2011. 

16. Christensen, T.P., F.J. Ascione, and R.P. 

Bagozzi, ‘‘Understanding How Elderly 

Patients Process Drug Information: A 

Test of a Theory of Information 

Processing.’’ Pharmaceutical Research, 

vol. 14, pp. 1589–1596, 1997. 

17. Mehta, A. and S.C. Purvis, ‘‘Consumer 

Response to Print Prescription Drug 

Advertising.’’ Journal of Advertising 

Research, vol. 43(2), pp. 194–206, 2003. 

18. Paulhus, D.L. and S. Vazire, ‘‘The SelfReport Method.’’ Handbook of Research 

Methods in Personality Psychology, vol. 

1, pp. 224–239, 2007. 

Dated: August 8, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–17360 Filed 8–13–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

The Biomedical Advanced Research 

and Development Authority (BARDA) 

AGENCY: Assistant Secretary for 

Preparedness and Response, HHS. 

ACTION: Notice. 

SUMMARY: The Biomedical Advanced 

Research and Development Authority 

(BARDA), Office of the Assistant 

Secretary for Preparedness and 

Response (ASPR), in the Department of 

Health and Human Services intends to 

provide a Single Source Cooperative 

Agreement to Janssen Research & 

Development, LLC. The Cooperative 

Agreement will support QuickFire 

Challenges to spur innovation in 

respiratory protection. The total 

proposed cost of the Single Source 

Cooperative Agreement is not to exceed 

$100,000 for a total of 12 months. 

DATES: 

Project Period: The period of 

performance is from July 30, 2018 to 

June 30, 2019. 

Award amount: Estimate $100,000. 

FOR FURTHER INFORMATION CONTACT: 

Sherrette.Funn@hhs.gov, 202–795–7714, 

Julie.Schafer@hhs.gov, 202–205–1435. 

SUPPLEMENTARY INFORMATION: The 

Biomedical Advanced Research and 

Development Authority (BARDA) is the 

program office for this Cooperative 

Agreement: 

Single Source Justification: Janssen 

Research & Development, LLC creates 

global challenges to spur innovation in 

health care in partnership with JLABS, 

a global network of open innovation 

ecosystems designed to support 

innovators and entrepreneurs in 

creating and accelerating innovative 

health care solutions. 

Janssen Research & Development, LLC 

and BARDA will collaborate on a global 

challenge for reimagined, transformative 

respiratory protection. Traditional 

respiratory protective devices used to 

protect against inhalation of harmful 

infectious agents were designed for use 

in occupational settings, to guard 

against inhalation of dangerous 

particulates. Disposable versions, such 

as N95 respirators, are only available for 

adults, must be fit-tested to ensure 

proper functioning, and can be 

uncomfortable to wear. In an outbreak of 

a novel or newly emerging respiratory 

disease, respiratory protection may be 

the only countermeasure available to 

protect health care workers and the 

general public. 

Janssen Research & Development, LLC 

will partner with JLABS, which exists to 

foster innovation in health care 

products and executes QuickFire 

Challenges for health care innovation. 

There is no direct equivalent of the 

QuickFire Challenge services for 

innovation specific to health care as is 

provided by JLABS. Its unique service 

will directly benefit BARDA’s mission 

to make available medical 

countermeasures to address health 

security threats. Supporting innovation 

is an authority provided to BARDA 

under the Public Health Service Act and 

partnering with a company providing a 

diverse array of products and leveraging 

its expertise and infrastructure has the 

potential to provide solutions to the 

challenges in developing new 

respiratory devices. 

Reimagined, innovative respiratory 

protection would contribute directly to 

ASPR’s mission to save lives and protect 

Americans against 21st Century health 

security threats. Respiratory protection 

is often the first line of defense, and a 

radically improved approach to protect 

both health care workers and the general 

public, including children, would truly 

improve our ability to respond to public 

health emergencies. By generating 

interest and focusing innovation efforts 

on reimagining respiratory protection, 

BARDA’s goal for the QuickFire 

Challenge is for the resulting innovative 

approaches to be eligible for continued 

testing and development and eventual 

regulatory approval, so that these 

revolutionary products can be widely 

available and used. 

Please submit an inquiry via the 

ASPR–BARDA Program Contact: Dr. 

Julie Schafer, Julie.Schafer@hhs.gov, 

202–205–1435. 

Robert P. Kadlec, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 2018–17381 Filed 8–13–18; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Pain Management Best 

Practices Inter-Agency Task Force 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 


amozie on DSK3GDR082PROD with NOTICES1